^
    Back
    Association details:
    Biomarker:EGFR amplification
    Cancer:Esophageal Squamous Cell Carcinoma
    Drug:Gilotrif (afatinib) (pan-HER inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

    Excerpt:
    ...Immunohistochemistry confirmed EGFR(3+) or EGFR-FISH-amplification or next generation sequencing confirmed EGFR-amplification....
    Trial ID:
    NCT03940976
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer
    Title:

    Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma

    Published date:
    08/04/2020
    Excerpt:
    As a predictive marker, a score derived from...EGFR amplifications and/or missense mutations demonstrated a significant association with the response to afatinib. The score based on the mutational status of EGFR...achieved a performance of an area under the curve of 0.86 in predicting the sensitivity of afatinib.
    DOI:
    10.1002/cncr.33123